Chen Jin

Chen Jin

Auto-generated profile, based on publicly available information

Chen Jin

School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
HTHongru Tao
Hongru Tao
CJChen Jin
Chen Jin
LZLiyuan Zhou
Liyuan Zhou
ZDZhenzhong Deng
Zhenzhong Deng
XLXiao Li
Xiao Li
YZYuanyuan Zhang
Yuanyuan Zhang
Despite the immense success of immune checkpoint blockade (ICB) in cancer treatment, many tumors, including melanoma, exhibit innate or adaptive resistance. Tumor-intrinsic T-cell deficiency and T-cell dysfunction have been identified as essential factors in the emergence of ICB resistance. Here, we found that protein arginine methyltransferase 1 (PRMT1) expression was inversely correlated with the number and activity of CD8+ T cells within melanoma specimen. PRMT1 deficiency or inhibition with DCPT1061 significantly restrained refractory melanoma growth and increased intratumoral CD8+ T cells in vivo. Moreover, PRMT1 deletion in melanoma cells facilitated formation of double-stranded RNA derived from endogenous retroviral elements (ERV) and stimulated an intracellular interferon response. Mechanistically, PRMT1 deficiency repressed the expression of DNA methyltransferase 1 (DNMT1) by attenuating modification of H4R3me2a and H3K27ac at enhancer regions of Dnmt1, and DNMT1 downregulation consequently activated ERV transcription and the interferon signaling. Importantly, PRMT1 inhibition with DCPT1061 synergized with PD-1 blockade to suppress tumor progression and increase the proportion of CD8+ T cells as well as IFNγ+CD8+ T cells in vivo. Together, these results reveal an unrecognized role and mechanism of PRMT1 in regulating antitumor T-cell immunity, suggesting PRMT1 inhibition as a potent strategy to increase the efficacy of ICB. Significance: Targeting PRMT1 stimulates interferon signaling by increasing expression of endogenous retroviral elements and double-stranded RNA through repression of DNMT1, which induces antitumor immunity and synergizes with immunotherapy to suppress tumor progression.

1 February 2024
Verified
Other
Open access
HTHongru Tao
Hongru Tao
CJChen Jin
Chen Jin
LZLiyuan Zhou
Liyuan Zhou
ZDZhenzhong Deng
Zhenzhong Deng
XLXiao Li
Xiao Li
YZYuanyuan Zhang
Yuanyuan Zhang
This file includes all supplemental data with figure legends.

1 February 2024
Verified
Other
Open access
PDF file
HTHongru Tao
Hongru Tao
CJChen Jin
Chen Jin
LZLiyuan Zhou
Liyuan Zhou
ZDZhenzhong Deng
Zhenzhong Deng
XLXiao Li
Xiao Li
YZYuanyuan Zhang
Yuanyuan Zhang
This file includes supplementary methods and reagents used in this study.

1 February 2024
Verified
Other
Open access
HTHongru Tao
Hongru Tao
CJChen Jin
Chen Jin
LZLiyuan Zhou
Liyuan Zhou
ZDZhenzhong Deng
Zhenzhong Deng
XLXiao Li
Xiao Li
YZYuanyuan Zhang
Yuanyuan Zhang
Despite the immense success of immune checkpoint blockade (ICB) in cancer treatment, many tumors, including melanoma, exhibit innate or adaptive resistance. Tumor-intrinsic T-cell deficiency and T-cell dysfunction have been identified as essential factors in the emergence of ICB resistance. Here, we found that protein arginine methyltransferase 1 (PRMT1) expression was inversely correlated with the number and activity of CD8+ T cells within melanoma specimen. PRMT1 deficiency or inhibition with DCPT1061 significantly restrained refractory melanoma growth and increased intratumoral CD8+ T cells in vivo. Moreover, PRMT1 deletion in melanoma cells facilitated formation of double-stranded RNA derived from endogenous retroviral elements (ERV) and stimulated an intracellular interferon response. Mechanistically, PRMT1 deficiency repressed the expression of DNA methyltransferase 1 (DNMT1) by attenuating modification of H4R3me2a and H3K27ac at enhancer regions of Dnmt1, and DNMT1 downregulation consequently activated ERV transcription and the interferon signaling. Importantly, PRMT1 inhibition with DCPT1061 synergized with PD-1 blockade to suppress tumor progression and increase the proportion of CD8+ T cells as well as IFNγ+CD8+ T cells in vivo. Together, these results reveal an unrecognized role and mechanism of PRMT1 in regulating antitumor T-cell immunity, suggesting PRMT1 inhibition as a potent strategy to increase the efficacy of ICB.Significance:Targeting PRMT1 stimulates interferon signaling by increasing expression of endogenous retroviral elements and double-stranded RNA through repression of DNMT1, which induces antitumor immunity and synergizes with immunotherapy to suppress tumor progression.

1 February 2024
Verified
Other
Open access
PDF file
HTHongru Tao
Hongru Tao
CJChen Jin
Chen Jin
LZLiyuan Zhou
Liyuan Zhou
ZDZhenzhong Deng
Zhenzhong Deng
XLXiao Li
Xiao Li
YZYuanyuan Zhang
Yuanyuan Zhang
This file includes supplementary methods and reagents used in this study.

1 February 2024
Verified
Other
Open access
PDF file
HTHongru Tao
Hongru Tao
CJChen Jin
Chen Jin
LZLiyuan Zhou
Liyuan Zhou
ZDZhenzhong Deng
Zhenzhong Deng
XLXiao Li
Xiao Li
YZYuanyuan Zhang
Yuanyuan Zhang
This file includes all supplemental data with figure legends.